Return to content in this issue

 

Successful Oral Dasatinib Desensitization in Immediate Hypersensitivity

Ruano-Zaragoza M*1,2,3, Torrent-Rodríguez A*4, Araujo-Sanchez G1,2,3, Ribó P1, Loli-Ausejo D1, Solis K1, Sánchez-Fernández MC1, Bolaños J5, Bolós U5, López C4, Ruiz S4, Pascal M3,5, Bartra J1,2,3, Muñoz-Cano R1,2,3

1Allergy Department, Hospital Clinic, Barcelona, Spain
2Clinical & Experimental Respiratory Immunoallergy, Institut Investigacions Biomediques August Pi I Sunyer (IDIBAPS), Barcelona, Spain
3RETIC Asma, Reacciones Adversas y Alergia (ARADyAL) and RICORS Red de Enfermedades Inflamatorias (REI), Madrid, Spain
4Pharmacy Department, Hospital Clinic, Barcelona, Spain
5Immunology Department, Centre de Diagnòstic Biomèdic (CDB), Hospital Clínic de Barcelona, Barcelona, Spain
*These authors contributed equally to this work and should be considered co-first authors. 

J Investig Allergol Clin Immunol 2024; Vol. 34(4)
doi: 10.18176/jiaci.0985

Key words: Oral desensitization, Dasatinib, drug allergy, tyrosine kinase inhibitors, basophil activation test